

## Technology Opportunity

Ref. No. IOR18P003

Title **EG-011 is a novel small molecule with *in vitro* and *in vivo* anti-tumor activity against lymphoma and other hematological cancers**

**Contact**  
Andrea Foglia  
Technology Transfer Office  
Via Vincenzo Vela 6  
6500 Bellinzona - Switzerland  
+41 58 666 4522  
andrea.foglia@usi.ch  
<http://ior.iosi.ch>



Background	Despite the improvements in the treatment of patients with lymphoma, still too many patients die for their disease and treatments with novel mechanism of action are needed.
Invention	<p>We developed a small molecule, EG-011, with <i>in vitro</i> anti-tumor activity against lymphomas and leukemias. The mechanism of action of EG-011 is novel and it is driven by targeting the protein WASP, an unique target not shared with other anti-lymphoma and anti-leukemia agents. The <i>in vitro</i> anti-tumor activity was also confirmed in an <i>in vivo</i> experiment with a mantle cell lymphoma xenograft.</p> <p>EG-011 is synergistic with multiple compounds currently used to treat patients with lymphomas (rituximab, bendamustine, venetoclax, ibrutinib and lenalidomide)</p> <p>Ref.: DOI: 10.1158/1538-7445.AM2019-4796</p>
Advantages	Our compound has an unique mechanism of action, making it optimal to be combined with various anti-tumor agents and active also in cases resistant to FDA approved agents.
Field of Use	Anti-cancer therapy (lymphoma / leukemia)
Patent Status	International patent application published (WO2019185117)
Keyword	cancer, lymphoma, WASP, WAS, ibrutinib, rituximab, venetoclax, anti-tumor, leukemia, Wiskott-Aldrich Syndrome
Technical Contact	<p>Prof. Dr. med. Francesco Bertoni francesco.bertoni@ior.usi.ch tel. +41 91 8200 367</p>